US2022211773A1PendingUtilityA1

Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains

Assignee: EVELO BIOSCIENCES INCPriority: Nov 15, 2017Filed: Jan 25, 2022Published: Jul 7, 2022
Est. expiryNov 15, 2037(~11.3 yrs left)· nominal 20-yr term from priority
C12N 1/20C12N 1/205A61P 37/06A61K 35/744A61K 2035/115C12R 2001/225A61K 45/05A61P 17/06A61P 29/00Y02A50/30
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are methods and compositions related to immune modulating Lactococcus strains useful as therapeutic agents. In certain embodiments, provided herein are methods of treating an immune disorder in a subject comprising administering to the subject a bacterial composition comprising Lactococcus lactis cremoris Strain A (ATCC Deposit Number PTA-125368).

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 45 . (canceled) 
     
     
         46 . A bacterial composition comprising  Lactococcus lactis cremoris  Strain A (ATCC Deposit Number PTA-125368) and a pharmaceutically acceptable carrier. 
     
     
         47 - 49 . (canceled) 
     
     
         50 . The bacterial composition of  claim 46 , wherein the bacterial composition formulated for oral, rectal, intravenous, intratumoral, or subcutaneous administration. 
     
     
         51 . The bacterial composition of  claim 46 , wherein at least 50% of the bacteria in the bacterial composition are  Lactococcus lactis cremoris  Strain A (ATCC Deposit Number PTA-125368). 
     
     
         52 . The bacterial composition of  claim 46 , wherein at least 90% of the bacteria in the bacterial composition are  Lactococcus lactis cremoris  Strain A (ATCC Deposit Number PTA-125368). 
     
     
         53 . The bacterial composition of  claim 46 , wherein substantially all of the bacteria in the bacterial composition are the immune modulating  Lactococcus  strain. 
     
     
         54 . The bacterial composition of  claim 46 , wherein the bacterial composition comprises at least 1×10 6  colony forming units (CFUs) of  Lactococcus lactis cremoris  Strain A (ATCC Deposit Number PTA-125368). 
     
     
         55 . The bacterial composition of  claim 54 , wherein the bacterial composition comprises at least 1×10 7  CFUs of  Lactococcus lactis cremoris  Strain A (ATCC Deposit Number PTA-125368). 
     
     
         56 . The bacterial composition of  claim 54 , wherein the bacterial composition comprises at least 1×10 8  CFUs of  Lactococcus lactis cremoris  Strain A (ATCC Deposit Number PTA-125368). 
     
     
         57 - 59 . (canceled) 
     
     
         60 . The bacterial composition of  claim 46 , wherein the bacterial composition comprises live bacteria. 
     
     
         61 . The bacterial composition of  claim 46 , wherein the bacterial composition comprises attenuated bacteria. 
     
     
         62 . The bacterial composition of  claim 46 , wherein the bacterial composition comprises killed bacteria. 
     
     
         63 . The bacterial composition of  claim 46 , wherein the bacterial composition comprises irradiated bacterium. 
     
     
         64 . The bacterial composition of  claim 63 , wherein the bacterial composition comprises gamma irradiated bacterium. 
     
     
         65 . The bacterial composition of  claim 46 , wherein administration of the bacterial composition treats an immune disorder. 
     
     
         66 . The bacterial composition of  claim 46 , wherein administration of the bacterial composition induces an immune response. 
     
     
         67 . The bacterial composition of  claim 46 , wherein the bacterial composition is formulated with an enteric coating or micro encapsulation. 
     
     
         68 - 79 . (canceled) 
     
     
         80 . The bacterial composition of  claim 46 , wherein the bacterial composition is substantially free of exopolysaccharides. 
     
     
         81 - 94 . (canceled) 
     
     
         95 . The bacterial composition of  claim 46 , wherein the bacterial composition is formulated for administration in solid form. 
     
     
         96 . The bacterial composition of  claim 46 , wherein the bacterial composition is formulated in a capsule.

Join the waitlist — get patent alerts

Track US2022211773A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.